With regard to neurodegenerative diseases, promising PrP-related therapeutic strategies include reduction of total or cell surface PrP levels (e.g., via antisense oligonucleotides (ASOs) [91, 94, 104] or other compounds [87]) and treatment with PrP-directed antibodies or other ligands (aiming to block membrane-bound PrP`s interaction with toxic conformers and/or to stabilize its native fold [85] (reviewed in [71])). This evidence concerns the gene PRNP and neurodegenerative disease.